> Oral presentation Novel drug targets for asthma and COPD
I have forgotten my password
08:30 - 10:30
Novel drug targets for asthma and COPD
General respiratory patient care, Physiology
London (United Kingdom)
Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study
D. Singh(Manchester, United Kingdom)
Anti-inflammatory effects of the JAK inhibitor tofacitinib in two murine house dust mite -driven models of asthma.
A. Pisano(Parma (PR), Italy)
Hydrogen sulphide donors prevent hyperreactivity of mice tracheas in an in vitro lipopolysaccharide-induced inflammation model
Y. Karaman-Kutluay(Ankara, Turkey)
Aerosolized TLR7 Imidazoquinoline Agonist Bronchodilates In Vivo
M. Drake(Portland, United States)
IL-33 blockade impacts mediators of persistence and exacerbation of chronic airway inflammation.
J. Allinne(Tarrytown, United States)
Targeting NADPH oxidase-2 reduces cigarette smoke-induced lung inflammation and skeletal muscle wasting in mice
I. Bernardo(Melbourne (VIC), Australia)
Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma
M. Suzuki(Tokyo, Japan)
. . .